Upload
ayame
View
34
Download
0
Embed Size (px)
DESCRIPTION
HuBio 543 September 24, 2007. Neil M. Nathanson K-536A, HSB 3-9457 [email protected] Muscarinic Antagonists. C. C. H 2 C. CH 2. CH. CH 2 OH. CHO. NCH 3. C. H. CH 2. CH. H 2 C. O. O. C. CH 2. CH. CH 2 OH. CHO. NCH 3. C. O. H. CH 2. C. CH. - PowerPoint PPT Presentation
Citation preview
Atropine
H2C
H2C
CH
NCH3
CH
CH2
CH2
CHOOC C
CH2OH
H
C
C
CH
NCH3
CH
CH2
CH2
CHOOC C
CH2OH
HO
H
H
Scopolamine
Tertiary Muscarinic Antagonists
Tertiary AntagonistsAtropine *Scopolamine *HomatropineTropicamineTolterodineOxybutynin
Quaternary AntagonistsN- methyl atropine *N- methyl scopolamineIpratropium *PropanthelineTiotropium*
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
0 2 4 6 8 10Dose of Atropine (µg/kg)
Heart
Rate
50
60
70
80
Biphasic Effect of Atropine on Human Heart Rate
Why the biphasic dose-response curve to atropine?
1. CNS- Low doses of atropine may act preferentially in the CNS to increase parasympathetic outflow
2. Presynaptic effect- Low doses of atropine may act preferentially on presynaptic mAChR on parasympathetic terminals, resulting in increased ACh release onto the heart
Presynaptic Muscarinic Receptors Inhibit AChRelease From Parasympathetic Terminals
ACh
ACh
mAChR ACh
mAChR
XXACh
ACh
ACh
Presynaptic Muscarinic Receptors Inhibit AChRelease From Parasympathetic Terminals
ACh
ACh
mAChR ACh
mAChR
XXACh
Therefore: Less ACh is released, Heart Rate is not slowed as much
Increased ACh Release and Bradycardia WhenPresynaptic mAChR Are Blocked by (Low Doses of)
Atropine
ACh
ACh
mAChR
ACh
mAChRACh
ACh
ACh
Atropine
0 2 4 6 8 10Dose of Atropine (µg/kg)
Heart
Rate
50
60
70
80
Biphasic Effect of Atropine on Human Heart Rate
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
Biphasic Effect of Atropine on Human Heart Rate
Low doses preferentially:1. Act in CNS to increase parasympathetic outflow- decreases HR
2. Blocks presynaptic receptor on parasympathetic nerve terminal-increases ACh release, decreases HRParasymp.
GanglionMR MR
High doses:Block mAChR on heart-Block effects of ACh, increases HR
80
60
40
20
0210.
5
SalivarySecretion
(-)Micturition
Speed(-)
Heart Rate(+)
Accomodation(-)
Increase or Decrease (%)
Atropine (mg/70 kg)
Sensitivity of Target Organs to Atropine
Toxic Effects of 3o mAChR Antagonists
• Visual problems• Constipation and urinary retention• Glaucoma in predisposed individuals• Hallucinations and delirium• Decreased sweating and salivation• Erectile problems/impaired vaginal lubrication
Can use AChE inhibitors as an antidote
Tricyclic anti-depressants can act as mAChR antagonists
(of smooth muscle)
Physostigmine reverses anti- muscarinic CNS effects of tricyclic anti-depressants
Ipratropium
N-methylatropine
H2C
H2C
CH
NCH3
CH
CH2
CH2
CHOOC C
CH2OH
H(H3C) 2HC
+
H2C
H2C
CH
NCH3
CH
CH2
CH2
CHOOC C
CH2OH
HH3C
+
Quaternary Muscarinic Antagonists
Tertiary AntagonistsAtropine *Scopolamine *HomatropineTropicamineTolterodineOxybutynin
Quaternary AntagonistsN- methyl atropine *N- methyl scopolamineIpratropium *PropanthelineTiotropium*
N-methylatropine does not cross membranes as well as atropine
N-methylatropine does not cross membranes as well as atropine
80
60
40200
100
CumulativeAdsorption
(%)Atropine
N-methylatropine
Distance From the Nose (cm.)100 20015050
Therapeutic uses of mAChR Antagonists
• (Preanesthetic medication)• Ophthalmological- mydriasis and cylcoplegia
• GI and Urinary Tract- decrease tone & motility
• Decrease excessive sweating• CV- block vagally-mediated bradycardia• CNS- motion sickness• Respiratory tract- bronchodilation
Therapeutic uses of mAChR Antagonists
• (Preanesthetic medication)• Ophthalmological- mydriasis and cylcoplegia
• GI and Urinary Tract- decrease tone & motility
• Decrease excessive sweating• CV- block vagally-mediated bradycardia• CNS- motion sickness• Respiratory tract- bronchodilation
Lumen
Gland
SMOOTH MUSCLE
Cholinergic Innervation
Lumen
Cholinergic Innervation of the Airways
Rates of Hospitalization in Control and Ipratropium Groups
0
10
20
30
40
50
60ControlIpratropium
Patients Hospitalized (%)
AllPatients
ModerateAsthma
SevereAsthma
Patient compliance is a big problem
Patients prescribed ipratropium inhalers:
-Self- reported compliance was 60- 70%
-This was confirmed by canister weight
BUT: Compliance was also determined by
electronic monitoring and found to be much poorer
Medilog: electronic inhaler monitor
Monitoring showed that only 15% of Monitoring showed that only 15% of subjects actuallysubjects actuallyused the inhaler as prescribed.used the inhaler as prescribed.
14% of patients actuated inhaler more 14% of patients actuated inhaler more than 100 times on the day of a visit.than 100 times on the day of a visit.
Patients want to be liked by their physicians
FromCNS
ACh
N
Synaptic Transmission Through a Sympathetic Ganglion:
To Target
M
MainPathway
ModulatoryPathway
Effect of Ganglionic Stimulants
+ Hexamethonium:
+ DMPP
+ DMPP
BP
BP
HR
HR
+ McN-A-343
+ McN-A-343
Muscarinic Receptors in Sympathetic Ganglia
• Excitatory (normally modulate transmission through the nicotinic pathway)
• Selectively activated by McN-A-343• (McN-A-343 therefore causes increased BP)
• Selectively blocked by pirenzepine
%ReceptorsBlocked
DRUG CONCENTRATION
Atropine(atria or ganglia) Pirenzepi
ne (ganglion)
Pirenzepine (atria)
Pirenzepine Selectively Blocks mAChR in Sympathetic Ganglia
Subtypes of mAChR• Five different mAChR in humans (all in CNS)• M1- in sympathetic ganglia (and adrenal medulla), activated by McN-A-343, blocked by pirenzepine
• M2- cardiac mAChR; can contribute to contraction of some smooth muscles; a presynaptic receptor on some nerve terminals
• M3- mediates contraction of smooth muscle, relaxation of vasculature, and secretion from many glands
Cevimeline• Selective M3 agonist• Used for treatment of xerostomia and Sjorgren’s syndrome
• Long-lasting sialogogic agent• May have fewer side effects than pilocarpine
Tiotropium• Selective M3 antagonist
– Very slow dissociation from M3 mAChR– 4° antagonist– like ipratropium, is an inhaled bronchodilator
• Used for treatment of COPD
Effect of Ganglionic Stimulants
+ Hexamethonium:
+ DMPP
+ DMPP
BP
BP
HR
HR
+ McN-A-343
+ McN-A-343